
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Barcelona, Spain - New research demonstrates the pathophysiology of itch may be more complex than once believed. Recently discovered pruritic pathways, such as those involving proteases or neuropeptides, are opening doors to new therapeutic targets for this uncomfortable, hard-to-control phenomenon.






